EUVIMEDEUVIMED entdecken
Crossref

Integrated double redo percutaneous valve replacement: simultaneous transcatheter aortic and mitral valve management

Hristian Hinkov iD, Chong Bin Lee iD, Dustin Greve iD, Christoph Klein, Marian Kukucka iD, Jörg Kempfert iD, Stephan Jacobs, Volkmar Falk iD, Henryk Dreger, Axel Unbehaun iD

European Journal of Cardio-Thoracic Surgery · 2025

DOI: 10.1093/ejcts/ezaf023 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cardio-Thoracic Surgery, 2025. Verfasst von Hristian Hinkov und 9 weiteren Autor:innen. Beteiligte Einrichtung: Deutsches Herzzentrum der Charité (DHZC), Department of Cardiothoracic and Vascular Surgery, Berlin, Germany. Hauptthemen laut MEDLINE: Mitral Valve, Transcatheter Aortic Valve Replacement, Reoperation, Aortic Valve. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES The growing elderly population contributes to an increasing prevalence of severe degenerative native aortic valve (AV) or mitral valve (MV) disease in combination with bio-prosthetic valve failure of prior implanted (aortic or mitral) bio-prostheses, as well as concomitant failure of both aortic and mitral bio-prosthetic valves. A combined surgical AV and MV replacement carries a markedly higher risk, especially in the redo setting. Transcatheter double-valve implantation (TDVI) is emerging as a promising alternative that may mitigate the risks of redo surgery. The evidence for TDVI is very limited. This study aims to address the current gap in the literature by analysing a large institutional series of single-stage TDVI. METHODS Single-centre retrospective analysis of all patients (n = 13) undergoing simultaneous transcatheter aortic valve implantation (TAVI) and transcatheter mitral valve implantation (TMVI) from October 2018 until April 2024. Primary end-points were Valve Academic Research Consortium-3 (VARC-3) and Mitral Valve Academic Research Consortium (MVARC) technical success, 30-day device success and early safety (MVARC procedural success). Secondary end-points included echocardiographic TDVI performance, adverse events, symptom change and survival. RESULTS The median age of patients was 77 years, with 7/13 (53.8%) females. Median EuroSCORE II was 16.9%. All patients presented with structural valve degeneration with severe haemodynamic valve deterioration according to the VARC-3 definition. Procedural outcomes showed 100% technical success. There was absence of 30-day mortality (0%). Thirty-day device success and early safety/MVARC procedural success were 100%. No major adverse events occurred. After TDVI, the median New York Heart Association functional class improved from III to II. CONCLUSIONS TDVI appears to be a safe and effective alternative to surgical redo double-valve replacement for selected patients. Our findings support the feasibility of TDVI with excellent early outcomes. Further prospective multicentre studies with larger cohorts are needed to validate the long-term effects and to establish TDVI as a guideline consideration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mitral ValveTranscatheter Aortic Valve ReplacementReoperationAortic ValveHeart Valve Prosthesis ImplantationHumansFemaleRetrospective StudiesMaleAged, 80 and overAgedHeart Valve ProsthesisTreatment Outcome

Stichwörter der Autor:innen

Double-valve replacementRedo valve surgeryStructural valve degenerationTranscatheter aortic valve implantationTranscatheter double-valve implantationTranscatheter mitral valve implantationValvular heart disease

Autor:innen und Institutionen

  • Deutsches Herzzentrum der Charité (DHZC), Department of Cardiothoracic and Vascular Surgery, Berlin, Germany.
  • Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • DZHK (German Center for Cardiovascular Research), Partner Site Berlin, Berlin, Germany.
  • Deutsches Herzzentrum der Charité (DHZC), Department of Cardiology, Angiology and Intensive Care Medicine, Berlin, Germany.
  • Deutsches Herzzentrum der Charité (DHZC), Department of Cardiac Anaesthesiology and Intensive Care Medicine, Berlin, Germany.
  • ETH Zurich, Department Health Sciences and Technology, Translational Cardiovascular Technology, Zurich, Switzerland.

ORCID-Profile: Hristian Hinkov, Chong Bin Lee, Dustin Greve, Marian Kukucka, Jörg Kempfert, Volkmar Falk, Axel Unbehaun

Zitieren

APA

Hinkov, H., Lee, C. B., Greve, D., Klein, C., Kukucka, M., Kempfert, J., Jacobs, S., Falk, V., Dreger, H., & Unbehaun, A. (2025). Integrated double redo percutaneous valve replacement: simultaneous transcatheter aortic and mitral valve management. European Journal of Cardio-Thoracic Surgery. https://doi.org/10.1093/ejcts/ezaf023

Vancouver

Hinkov H, Lee CB, Greve D, Klein C, Kukucka M, Kempfert J, et al. Integrated double redo percutaneous valve replacement: simultaneous transcatheter aortic and mitral valve management. European Journal of Cardio-Thoracic Surgery. 2025. doi:10.1093/ejcts/ezaf023

BibTeX
@article{Hinkov2025,
  author = {Hinkov, Hristian and Lee, Chong Bin and Greve, Dustin and Klein, Christoph and Kukucka, Marian and Kempfert, Jörg and Jacobs, Stephan and Falk, Volkmar and Dreger, Henryk and Unbehaun, Axel},
  title = {Integrated double redo percutaneous valve replacement: simultaneous transcatheter aortic and mitral valve management},
  journal = {European Journal of Cardio-Thoracic Surgery},
  year = {2025},
  doi = {10.1093/ejcts/ezaf023}
}
Kostenlos starten →